Mesoblast Limited (ASX:MSB) Associate Company Angioblast Features At UBS Life Sciences Investor Conference In United States

Melbourne, Sep 24, 2009 AEST (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced that its United States-based associate company, Angioblast Systems Inc., was today featured at the 2009 UBS Global Life Sciences Conference underway in New York.

International investors were updated on the exciting progress of Angioblast's lead clinical programs, including the trials for congestive heart failure and bone marrow transplantation. Positive outcomes from these trials are expected to underpin Angioblast's near-term corporate and commercial activities.

The ninth annual UBS Global Life Sciences Conference is among the largest healthcare investor conferences in the world with around 3,500 attendees.

Contact

Julie Meldrum Corporate Communications Director Mesoblast Limited Tel: +61-3-9639-6036 Mob: +61-419-228-128 Email: julie.meldrum@mesoblast.com www.mesoblast.com